Press

Cybin Provides Update on its Intellectual Property Portfolio

Oct 7 • 3 min read

Cybin Inc. (NEO:CYBN | NYSE AMERICAN:CYBN)), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics®, is pleased to provide an update on its intellectual property progress in support of its research and development strategy. The Company continues to prioritize the development of in-house IP and licensing opportunities that support its active development programs and future novel…

Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

Oct 7 • 3 min read

Revive Therapeutics Ltd. (OTCQB: RVVTFC | SE: RVV | FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, today announced an update on the Company’s U.S. Food & Drug Administration Phase 3 clinical trial (the “Study”) (NCT04504734) to evaluate the safety and efficacy of…

PharmAla Biotech ready to assist Alberta Government with Clinical MDMA supply

Oct 6 • 3 min read

PharmAla Biotech (CSE: MDMA), currently the only manufacturer of GMP MDMA in Canada, stands ready to assist the Government of Alberta in supplying patients with clinical-grade drug product. However, many questions remain about how the Alberta government intends to deliver psychedelic molecules to patients under this new framework “As the only manufacturer of clinical-grade MDMA in North America we are completely committed to…

Silo Pharma to Present at the Dawson James Small Cap Growth Conference on October 12

Oct 6 • 2 min read

Silo Pharma, Inc. (Nasdaq: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that CEO Eric Weisblum will present and host investor meetings at the 7th Annual Dawson James Small Cap Growth Conference being held Wednesday, October 12, 2022, at the Wyndham Grand Hotel in Jupiter, Florida. Presentation: The…

Alberta Puts Patients First By Regulating Psychedelic Therapy: Optimi Health

Oct 6 • 4 min read

Optimi Health Corp. (CSE: OPTI | OTCQX: OPTHF | FRA: 8BN), a leading Canadian-based company licensed by Health Canada to produce and supply natural, EU-GMP grade psilocybin and other psychedelic substances, most notably MDMA, is applauding the government of Alberta’s decision to regulate some psychedelics for therapeutic use in the province. The proposed framework as…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435